{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:43:33Z","timestamp":1789746213688,"version":"4.0.1"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have been associated with neurological immune related adverse events (irAE-N) and patients with ICI toxicity may present with neurological or ocular symptoms. Furthermore, patients on ICI may initially present to oncology or neurology. We report a case series of 3 patients treated with ICIs presenting with diplopia or ptosis, found to have concurrent myocarditis in addition to immune-related myopathy (irMyopathy) or myasthenia gravis (irMG). None of the patients described cardiac symptoms, underscoring the importance of screening for myocarditis in patients presenting with diplopia and\/or other neuromuscular symptoms which may suggest either irMyopathy or irMG.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac033","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T07:17:04Z","timestamp":1643786224000},"page":"e402-e405","source":"Crossref","is-referenced-by-count":14,"title":["Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-5667","authenticated-orcid":false,"given":"John Y","family":"Rhee","sequence":"first","affiliation":[{"name":"Mass General Brigham, Department of Neurology, Harvard Medical School, Boston, MA, USA"},{"name":"ATLANTES Research Program, Institute for Culture and Society, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"Torun","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G","family":"Neilan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Division of Cardiology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C","family":"Guidon","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Division of Neuromuscular Medicine, Department of Neurology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"issue":"14","key":"2022050615365927100_CIT0001","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"issue":"18","key":"2022050615365927100_CIT0002","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2022050615365927100_CIT0003","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.3899\/jrheum.090562","article-title":"Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies","volume":"36","author":"Aggarwal","year":"2009","journal-title":"J Rheumatol"},{"key":"2022050615365927100_CIT0004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun"},{"issue":"7","key":"2022050615365927100_CIT0005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"2022050615365927100_CIT0006","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"17","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/5\/e402\/43590582\/oyac033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/5\/e402\/43590582\/oyac033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T11:37:16Z","timestamp":1651837036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/5\/e402\/6555085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":6,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2022,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac033","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,3,28]]}}}